Moderna, Inc. (NASDAQ:MRNA) is one of the stocks Jim Cramer was recently asked about. Noting that the company is working on a ...

CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David ...

BofA lifted its price target to $27 from $24 while keeping an 'Underperform' rating on the shares. ・The update followed the ...

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update ...

Moderna Inc.’s chief executive officer said the company doesn’t plan to invest in new late-stage vaccine trials because of ...

Moderna, Inc. vs. Novavax, Inc.: cost cuts, vaccine pipeline catalysts, and valuations. Click for this comparison of NVAX and ...

Moderna will continue to lead clinical development and manufacturing for mRNA-3927 Moderna to receive up to $160 million in upfront and near-term development and regulatory milestones, in addition to ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

Moderna, Inc. stock is up ~60% YTD on cancer vaccine trial data, 2026 readouts, and 2025 financials. Click for this updated look at MRNA stock prospects.

January 26, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 ...

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...